louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02197195: Sugars-sweetened Beverages and Exercise on Glycaemic Response and Subjective Appetite in Children
Official title: The Role of Chocolate Milk and Fruit Drink on Subjective Appetite and Glycaemic Response With or Without Exercise in Normal Weight 9-14 Year Old Boys
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glycemic Control
Subjective Appetite
Lead sponsor: Toronto Metropolitan University
Sponsor class: OTHER
First posted: 2014-07-22
Enrollment: 8
Sex: MALE
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of the study is to understand the role chocolate milk compared to a fruit drink, with and without exercise, on glycaemic regulation and subjective appetite in children. The investigators hypothesize that chocolate milk in combination with exercise will have the greatest effect attenuating glycaemic response. Blood glucose will be measured by finger prick following drink consumption (0 min) and exercise or sitting (15 min), and at 65 minutes. Subjective appetite will be measured at 0, 20, 35, 50 and 65 minutes.


Eligibility criteria: Inclusion Criteria:

* Healthy, boy, born at full term and normal birth weight

Exclusion Criteria:

* Girls, have significant learning, behavioral, or emotional difficulties

Primary outcomes:
measure: Blood Glucose (mmol/L)
timeFrame: at baseline (0), 20 and 65 minutes
Secondary outcomes:
measure: Subjective Appetite (mm)
timeFrame: 0 - 65 mins
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Ryerson University
state: Ontario
Study officials:
References:
Clinical trial NCT03755895: Contribution of Hypnosis to Anxiety and Pain in Brachytherapy Patients
Official title: Randomized Trial Comparing the Hypnosis Versus Standard Care of Anxiety and Pain in Patients With Brachytherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cancer
Brachytherapy
Keywords: Cancer
hypnosis
care management
Lead sponsor: Institut de Cancérologie de Lorraine
Sponsor class: OTHER
First posted: 2018-11-28
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Formal hypnosis is a non-drug technique known to decrease anxiety and pain during the preoperative procedure.

In brachytherapy, the practice of hypnosis has been shown to be feasible and beneficial for patients treated for prostate cancer The goal of the study is to demonstrate the added value of hypnosis during a brachytherapy detachment by improving the comfort of the patient.

The investigators want to evaluate the contribution of hypnosis during brachytherapy detachment by quantifying the anxiety and pain felt by the patient during the procedure.


Eligibility criteria: Inclusion Criteria:

* Adult patients ≥ 18 and ≤ 80 years
* Patients expected to benefit a brachytherapy detachment Under KALINOX® for one of the types of applications described below:

  * Deep interstitial application: anal canal, vagina, vulva
  * Gynecological application: mold, Utrecht® system or Venezia® system
* Ability to provide written informed consent
* Patients affiliated to the social security system

Exclusion Criteria:

* Minor and patients over 80 years old
* Patients with major hearing loss
* Patients who had recent ocular surgery with oculiare gas injection.
* Patients suffering from psychotic disorders, and dementias.
* Patients who do not understand the French language
* Patients under guardianship or deprived of liberty
* Patients with a contraindication to the administration of KALINOX®

Primary outcomes:
measure: Anxiety evaluation
timeFrame: 1day
Secondary outcomes:
measure: Pain evaluation: numeric scale
timeFrame: 1 day
measure: Anxiety evaluation
timeFrame: 1 day
measure: Patient's perception of the care
timeFrame: 1day
measure: Time of brachytherapy detachment
timeFrame: 1day
measure: Realization of the brachytherapy detachment
timeFrame: 1day
Other outcomes:
Locations:
city: Vandœuvre-lès-Nancy
country: France
facility: Institut de Cancérologie de Lorraine
Study officials:
affiliation: Institut de Cancérologie de Lorraine
name: Sophie RENARD, Md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02631395: The Effect of a Shoulder Training Program to Prevent Shoulder Pain Among Girls in Junior Team Handball
Official title: The Effect of a Shoulder Training Program to Prevent Shoulder Pain Among Girls in Junior Team Handball
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Shoulder Pain
Keywords: Exercise movement techniques
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
First posted: 2015-12-16
Enrollment: 106
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Very little is known about the potential for preventing the prevalence of shoulder complaints in handball players, particularly younger players. The aim of this study is to evaluate the effect of a shoulder training program on shoulder pain during a season of team handball.

Detailed description: Six teams, consisting of 13 to 25 players each, were randomized into two groups throughout their competition seasons. Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training. Effects of this strength--training program were evaluated by comparing pre-- and post--training data from a survey on shoulder complaints based on a self--report questionnaire (quick DASH) and Visual Analogue Scale (VAS). The players completed the VAS on pain once a month. In addition to that the players were tested in a maximum push up test, dynamometer test for internal and external rotation strength in the shoulder and throwing distance in the pre- and posttest.

Eligibility criteria: Inclusion Criteria:

- team handball players in the top division in the J16 class in the Trøndelag region in Norway

Exclusion Criteria:

- previous shoulder operations og fractures in the shoulder region

Primary outcomes:
measure: Shoulder pain (Visual Analogue Scale)
timeFrame: 7 months
Secondary outcomes:
measure: Shoulder strength
timeFrame: 7 months
measure: Push ups
timeFrame: 7 months
measure: Throwing distance
timeFrame: 7 months
measure: Shoulder function (Quick DASH)
timeFrame: 7 months
Other outcomes:
Locations:
Study officials:
affiliation: Norwegian University of Science and Technology
name: Jan Harry Størksen
role: STUDY_DIRECTOR
References:
citation: Osteras H, Sommervold M, Skjolberg A. Effects of a strength-training program for shoulder complaint prevention in female team handball athletes. A pilot study. J Sports Med Phys Fitness. 2015 Jul-Aug;55(7-8):761-7. Epub 2014 Dec 17.
Clinical trial NCT04196595: Apple Women's Health Study
Official title: Apple Women's Health Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Menstrual Cycle
Ovulation
Menstruation
Polycystic Ovary Syndrome
Infertility
Menopause
Reproduction
Reproductive Health
Keywords: Menstruation
Menstrual Cycle
Ovulation
Polycystic Ovary Syndrome
Infertility
Menopause
Reproduction
Reproductive Health
Lead sponsor: Apple Inc.
Sponsor class: INDUSTRY
Collaborators: name: Harvard School of Public Health (HSPH)
name: National Institute of Environmental Health Sciences (NIEHS)
First posted: 2019-12-12
Enrollment: 500000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Convenience sampling of individuals who have ever menstruated and meet other eligibility criteria

Brief summary: This is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including PCOS, infertility and breast cancer.The study will be hosted within the Research app(available on App Store), which allows a user to find, enroll, and participate in Apple-supported health-related research studies.


Eligibility criteria: Inclusion Criteria:

* Have menstruated at least once
* Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico)
* Live in the United States of America
* Be comfortable communicating in written and spoken English
* Have installed the Apple Research app on your iPhone
* Not share your iCloud account or iPhone with anyone else
* Be willing and able to provide informed consent to participate in the study

Primary outcomes:
measure: Identify Menstrual Cycle Patterns
timeFrame: Up to 10 years
measure: Epidemiologic Description of Menstrual Cycle
timeFrame: Up to 10 years
Secondary outcomes:
measure: Determine prevalence of gynecologic health conditions
timeFrame: Up to 10 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Harvard T.H. Chan School of Public Health
state: Massachusetts
Study officials:
affiliation: Harvard School of Public Health (HSPH)
name: Michelle A Williams, SM, ScD
role: PRINCIPAL_INVESTIGATOR
affiliation: Harvard School of Public Health (HSPH)
name: Russ B Hauser, MD, MPH, ScD
role: PRINCIPAL_INVESTIGATOR
affiliation: Harvard School of Public Health (HSPH)
name: Brent A Coull, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Harvard School of Public Health (HSPH)
name: Shruthi Mahalingaiah, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03188614: Crystalloids for AKI in Shock Patients
Official title: Different Crystalloids on the Incidence of Acute Kidney Injury in Shock Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Shock
Keywords: shock
crystalloid
acute kidney injury
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2017-06-15
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Fluid resuscitation is important in shock therapy, but the choice of fluids, especially the choice of crystalloid is under debate. It is said that normal saline is related to hyperchloremia， which might lead to acute kidney injury. Thus the hypothesis of the study is to explicit whether balanced salt solution could reduce the incidence of acute kidney injury when compared with normal saline.


Eligibility criteria: Inclusion Criteria:

* Shock patients

Exclusion Criteria:

* History of chronic renal failure

Primary outcomes:
measure: Incidence of acute kidney injury
timeFrame: 28-day
Secondary outcomes:
measure: Usage of renal replacement of therapy
timeFrame: 28-day
Other outcomes:
Locations:
Study officials:
affiliation: Southeast University
name: Haibo Qiu, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03757195: Augmentation of Maxillary Horizontal And Vertical Bone Deficiency Using Mineralized Plasmatic Matrix
Official title: Augmentation of Maxillary Horizontal And Vertical Bone Deficiency Using Mineralized Plasmatic Matrix
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Alveolar Ridge Abnormality of Maxilla
Keywords: Mineralized plasmatic matrix
sticky bone
plasma
autogeous fibrin glue
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-11-28
Enrollment: 28
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A new technique of grafting introduce called Mineralized plasmatic matrix. This technique can be used in grafting in anterior zone giving a good results and bone substitution occur using allograft or xenograft.

The bone graft have a good consistency when it mixed with plasma give easy application, strength and stability of the graft. Also plasma rich with CGF (Cellular growth factors).

Detailed description: Patients suffering from anterior maxillary vertical and horizontal bone loss will be treated using a xeno-graft mixed with the same patient plasma that extracted from his own blood during the operation this graft will be stabilized by collagen membrane and surgical tags.

Patients will be follow up for 6 months to measure amount of bone loss of the xeno-graft during this period post operative using C.B.C.T

Eligibility criteria: Inclusion Criteria:

* Age: from 20 to 40 years old
* no history of previous grafting.
* no History of previous implant placement
* Medically Free e.g no debilitating diseases

Exclusion Criteria:

* Smoker patients.
* Alcoholic patients
* Pregnant.
* Drug Abusers.
* Hypertensive , Diabetic, having Problems or disease in Kidney and/or liver.
* Thyroid Disease.
* Problem in Vit.D absorption or in calcitonin hormone secretion.
* History of blood transfusion or donating blood less than 4 months.
* Patient under Corticosteroid therapy.
* Neurologicaly unstable patients.
* History of radiotherapy or chemo-therapy.
* Patient undergo Spect C.T Scan less than 4 Months .

Primary outcomes:
measure: amount of bone loss
timeFrame: change from baseline at 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo Univerisity
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
affiliation: Cairo University
name: Tarek I. Abdallah, P.H.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT04143295: Rescue of Infants With MCT8 Deficiency
Official title: Rescue of Infants With MCT8 Deficiency
Study type: EXPANDED_ACCESS
Overall status: AVAILABLE
Conditions: Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2019-10-29
Sex: MALE
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no

Brief summary: Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.


Eligibility criteria: Inclusion Criteria

* Genetic Confirmation: Male fetus or fetuses (including monozygotic twin pregnancies) must have a confirmed MCT8 gene mutation.
* Family History: A previously born child or children with a severe, typical phenotype and an MCT8 gene mutation identical to that of the fetus.
* Alternatively, the mother or a sister must have a relative with a known MCT8 defect.
* Parental Decision: Parental refusal to terminate the pregnancy despite the diagnosis of MCT8 deficiency.
* Compliance and Availability: Willingness of the parents to comply with all study procedures and ensure availability for the duration of the study.

Exclusion Criteria:

• Pregnancy-Related Factors: Dizygotic (non-identical) twin pregnancy (unless only one fetus is confirmed with the MCT8 mutation, and the unaffected fetus will not be treated).

Parental decision to terminate the pregnancy.

• Maternal Medical Conditions: Hyperthyroidism requiring treatment. Significant liver or kidney insufficiency. Congestive heart failure. Hyperemesis gravidarum unresponsive to treatment.

* Significant cardiac conditions, including:
* Atrial fibrillation or other arrhythmias.
* Unstable angina.
* Coronary heart disease.
* Medications:

Current use of sympathomimetic therapy. Anticoagulant therapy. Use of Cytochrome P450 2C9 (CYP2C9) inhibitors with a narrow therapeutic index.

• Other Factors: Major illness or recent major surgery within four weeks of baseline visit 1, unrelated to MCT8 deficiency.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami, Miller School of Medicine
state: Florida
Study officials:
affiliation: University of Miami
name: Roy E Weiss, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04802395: Real World Evidence Clinical Utility Study of KidneyIntelX
Official title: Real World Evidence Clinical Utility Study of KidneyIntelX in Patients With Type 2 Diabetes and Chronic Kidney Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Kidney Diseases
Diabetic Kidney Disease
Lead sponsor: Renalytix AI, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Mount Sinai Hospital, New York
First posted: 2021-03-17
Enrollment: 10000
Sex: ALL
Minimum age (years): 23
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Type 2 diabetes and existing chronic kidney disease stages 1-3.

Brief summary: The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.


Eligibility criteria: Inclusion Criteria:

* Individuals with Type 2 diabetes and concurrent chronic (diabetic) kidney disease (G3a-G3b or G1-G2, A2-A3) per KDIGO CKD staging.

Exclusion Criteria:

* Patents without the appropriate characteristics as identified in the KidneyIntelX intended use population.
* Patients with eGFR \<30 or ≥ 60 ml/min/1.73m2 without albuminuria.
* Patients with ESRD or on renal recovery treatments at time of enrollment.
* Patients who are pregnant at the time of enrollment.
* Patients who are currently hospitalized.
* Patients without minimum 6 month pre-baseline KidneyIntelX medical history.
* Patients who are currently on Enbrel.

Primary outcomes:
measure: Referrals
timeFrame: 6 Months
measure: Statins and or ACEi/ARB
timeFrame: 6 Months
measure: HbA1c
timeFrame: 6 Months
measure: SGLT2/ GLP1
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Mount Sinai Health System
state: New York
Study officials:
References:
Clinical trial NCT06935695: Surveillance Versus Bronchoscopy After Airway Stenting
Official title: Surveillance Versus Prn bronChOscoPy aftEr aIrway stenTing (SCOPE-IT)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Bronchial Stents
Keywords: Airway
Stent
Bronchoscopy
Surveillance
Lead sponsor: Icahn School of Medicine at Mount Sinai
Sponsor class: OTHER
First posted: 2025-04-20
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Randomized, pilot study that evaluates surveillance bronchoscopy versus no surveillance for patients that undergo tracheobronchial stenting


Eligibility criteria: Inclusion Criteria:

* All adult patients that undergo central airway (trachea, main stem bronchi and bronchus intermedius) stenting.

Exclusion Criteria:

* Inability to obtain informed consent due to cognitive, neurologic or psychiatric impairment.
* Lobar or segmental stents alone
* Terminally ill patients considered too sick to undergo a follow-up surveillance bronchoscopy
* Stent insertion as a trial for excessive central airway collapse (as the duration of these stents is only 1-2 weeks)
* Patients with a tracheostomy (as these patients can undergo frequent in-line suctioning that can affect the outcomes being assessed)

Primary outcomes:
measure: Number of stent-related complications warranting an intervention
timeFrame: 3 months after enrollment
Secondary outcomes:
measure: Number of unscheduled visits due to stent-related complications
timeFrame: 3 months after enrollment
measure: Number of urgent care or emergency room visits due to stent-related complications
timeFrame: 3 months after enrollment
measure: Number of hospitalizations due to stent-related complications
timeFrame: 3 months after enrollment
measure: Number of stent-related complications as detected during a bronchoscopy or on cross-sectional imaging
timeFrame: 3 months after enrollment
measure: Protocol Feasibility Composite Score
timeFrame: 3 months after enrollment
Other outcomes:
Locations:
city: New York
country: United States
facility: The Mount Sinai Health System
state: New York
Study officials:
affiliation: Icahn School of Medicine
name: Udit Chaddha, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01319695: Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Infertility
Keywords: corifollitropin alfa
FSH ovarian stimulation
IVF
Lead sponsor: National and Kapodistrian University of Athens
Sponsor class: OTHER
First posted: 2011-03-22
Enrollment: 140
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The use of corifollitropin alfa is superior in terms of pregnancy outcome parameters as compared to recombinant follicle stimulating hormone (FSH) during ovarian stimulation protocols in women undergoing in vitro fertilisation.


Eligibility criteria: Inclusion Criteria:

* Women aged 18-36 years old with a body weight of more than 60 kg up to 90 kg
* BMI of 18-32 kg/m2
* Menstrual cycle length of 23-35 days
* An indication for controlled ovarian stimulation for IVF or ICSI

Exclusion Criteria:

* history of an endocrine abnormality
* abnormal outcome of blood biochemistry or hematology
* abnormal cervical smear
* chronic disease
* uterine pathology that interfering with the COS treatment (e.g. fibroids ≥ 5 cm)

Primary outcomes:
measure: no of oocytes (>2 between groups)
timeFrame: at egg recovery, through study completion, an average of 2 years
Secondary outcomes:
measure: Clinical pregnancy rate cancellation rate miscarriage rate ectopic pregnancy rate
timeFrame: 3 weeks after embryo transfer
measure: Ongoing pregnancy rate
timeFrame: 12 weeks after embryo transfer
measure: miscarriage rate
timeFrame: through study completion, an average of 2 years
measure: live birth rate
timeFrame: through study completion, an average of 2 years
Other outcomes:
Locations:
city: Athens
country: Greece
facility: 3rd Department of Obstetrics and Gynecology, Assisted Reproduction Unit
state: Chaidari
city: Athens
country: Greece
facility: Attikon University Hospital
state: Chaidari
Study officials:
References:
citation: Siristatidis C, Dafopoulos K, Christoforidis N, Anifandis G, Pergialiotis V, Papantoniou N. Corifollitropin alfa compared with follitropin beta in GnRH-antagonist ovarian stimulation protocols in an unselected population undergoing IVF/ICSI. Gynecol Endocrinol. 2017 Dec;33(12):968-971. doi: 10.1080/09513590.2017.1323203. Epub 2017 May 16.